Clinical Case Study: Targeting BCMA With ADCs in MM

Download this slideset based on the content from a live satellite symposium with a case study of the antibody–drug conjugate belantamab mafodotin and the potential for ocular toxicity while receiving this treatment for myeloma.
Paul G. Richardson, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 507 KB
Released: November 12, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
GlaxoSmithKline

Related Content

Slides from Clinical Care Options (CCO) with key findings on BTK inhibitors in CLL and MCL from the 2022 ASCO, EHA, Pan Pacific, ESMO, and SOHO meetings

Released: June 27, 2022

Experts highlight key studies presented at the 2022 EHA annual meeting in this commentary from Clinical Care Options (CCO)

Stéphane de Botton, MD Jesús F. San-Miguel, MD, PhD Alessandra Tedeschi, MD Released: June 20, 2022

Phase II trial shows high response rates and high 3-year EFS and OS rates with crenolanib plus 7+3 chemotherapy in newly diagnosed FLT3-mutated AML, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Results from retrospective Pre-MEASURE study evaluating the prognostic value of NGS-MRD testing in patients with AML in first remission prior to allogeneic HCT, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings